Anti-inflammatory effect of pregabalin on acetic acid-induced colitis in the rats. 2022

Azadeh Motavallian, and Ehsan Zamani, and Saba Bouzari, and Farzam Rezaeyan, and Paridokht Karimian, and Mehdi Evazalipour
Department of Pharmacology and Toxicology, School of Pharmacy, Guilan University of Medical Sciences, Rasht, I.R. Iran.

OBJECTIVE Inflammatory bowel disease (IBD) is a chronic gastrointestinal disease characterized by the inflammation of the intestine. The available medicinal treatments for IBD are not efficacious enough since they exert various adverse effects. Therefore, the search for new therapeutic agents should be continued. The present study aimed to assess the anti-inflammatory effects of pregabalin on acetic acid-induced colitis in rats. METHODS Using 2 mL of 3% acetic acid solution, colitis was intra-rectally induced in rats. Animals were randomly divided into 6 groups including the normal group, colitis control group, pregabalin treatment groups (30, 50, and 100 mg/kg; i.p., respectively), and dexamethasone treatment group (1 mg/kg; i.p.). Macroscopic, microscopic, and biochemical (myeloperoxidase, tumor necrosis factor-alpha, interleukin-6, and interleukin-1 beta) examinations were used to evaluate the efficacy of pregabalin in the inflamed colon. RESULTS All the applied doses of pregabalin significantly decreased the severity of macroscopic and microscopic colonic damages including ulcer severity, ulcer area, percentage of necrosis, and total colitis index compared to the colitis control group. These results were confirmed by the reduced colonic concentration of tumor necrosis factor-alpha, interleukin-6, interleukin-1 beta, and myeloperoxidase activity. CONCLUSIONS Results of this study indicated that pregabalin administration has beneficial effects upon the treatment of experimental colitis, which might be partly due to its anti-inflammatory properties.

UI MeSH Term Description Entries

Related Publications

Azadeh Motavallian, and Ehsan Zamani, and Saba Bouzari, and Farzam Rezaeyan, and Paridokht Karimian, and Mehdi Evazalipour
December 2012, Inflammation,
Azadeh Motavallian, and Ehsan Zamani, and Saba Bouzari, and Farzam Rezaeyan, and Paridokht Karimian, and Mehdi Evazalipour
February 2024, Inflammation,
Azadeh Motavallian, and Ehsan Zamani, and Saba Bouzari, and Farzam Rezaeyan, and Paridokht Karimian, and Mehdi Evazalipour
January 2014, Advanced biomedical research,
Azadeh Motavallian, and Ehsan Zamani, and Saba Bouzari, and Farzam Rezaeyan, and Paridokht Karimian, and Mehdi Evazalipour
March 2014, Avicenna journal of phytomedicine,
Azadeh Motavallian, and Ehsan Zamani, and Saba Bouzari, and Farzam Rezaeyan, and Paridokht Karimian, and Mehdi Evazalipour
December 2002, Vascular pharmacology,
Azadeh Motavallian, and Ehsan Zamani, and Saba Bouzari, and Farzam Rezaeyan, and Paridokht Karimian, and Mehdi Evazalipour
January 1999, Pharmacological research,
Azadeh Motavallian, and Ehsan Zamani, and Saba Bouzari, and Farzam Rezaeyan, and Paridokht Karimian, and Mehdi Evazalipour
January 1999, Pharmacological research,
Azadeh Motavallian, and Ehsan Zamani, and Saba Bouzari, and Farzam Rezaeyan, and Paridokht Karimian, and Mehdi Evazalipour
August 2017, Research in pharmaceutical sciences,
Azadeh Motavallian, and Ehsan Zamani, and Saba Bouzari, and Farzam Rezaeyan, and Paridokht Karimian, and Mehdi Evazalipour
January 2020, Avicenna journal of phytomedicine,
Azadeh Motavallian, and Ehsan Zamani, and Saba Bouzari, and Farzam Rezaeyan, and Paridokht Karimian, and Mehdi Evazalipour
January 2015, Research in pharmaceutical sciences,
Copied contents to your clipboard!